Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peptide therapeutics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Peptide therapeutics. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-001998-25 Sponsor Protocol Number: D/P2/04/2 Start Date*: 2004-09-28
    Sponsor Name:Diamyd Therapeutics AB
    Full Title: A placebo-controlled study to investigate the impact of DiamydTM on the diabetic status of patients with LADA (Latent Autoimmune Diabetes in Adult).
    Medical condition: Patients for the proposed study are those with Latent Autoimmune Diabetes in Adults (LADA). The presence of GAD 65 antibodies in this group identifies a single category of diabetes patients with o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004803-15 Sponsor Protocol Number: 5051-102 Start Date*: 2023-09-18
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: An Open-Label Extension Study for Patients with Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002219-25 Sponsor Protocol Number: ITCA650-CLP-107 Start Date*: 2014-09-16
    Sponsor Name:Intarcia Therapeutics, Inc.
    Full Title: A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) EE (Completed) FI (Completed) DE (Completed) DK (Completed) ES (Completed) PL (Completed) BG (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003666-20 Sponsor Protocol Number: P1606-SUR-O25 Start Date*: 2023-05-09
    Sponsor Name:Immunovaccine Technologies Inc. (IMV Inc.)
    Full Title: Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects with Platinum-Resistant, Epithelial Ovarian Cancer (AVALON)
    Medical condition: Platinum Resistant Epithelial Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033160 Ovarian epithelial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015929-37 Sponsor Protocol Number: 1001 Start Date*: 2010-09-02
    Sponsor Name:Andromeda Biotech Ltd, 42 Hayarkon st, Yavne, 81227, Israel
    Full Title: A PHASE III, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF DIAPEP277® IN NEWLY DIAGNOSED TYPE 1 DIABETES SUBJECTS
    Medical condition: Type I diabetes
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) DE (Completed) IT (Completed) AT (Completed) CZ (Completed) LT (Completed) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-003764-30 Sponsor Protocol Number: D/P2/04/3 Start Date*: 2004-12-13
    Sponsor Name:Diamyd Therapeutics AB
    Full Title: A Phase II, Randomised, Double-Blind, Placebo-controlled, Multi-centre Study to Investigate the Impact of Diamyd on the Progression of diabetes in Patients Newly Diagnosed with Type 1 Diabetes Mell...
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001189-40 Sponsor Protocol Number: APD811-303 Start Date*: 2023-04-05
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION
    Medical condition: Pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) CZ (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) HR (Completed) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000755-40 Sponsor Protocol Number: ATB200-03 Start Date*: 2019-04-08
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Algluc...
    Medical condition: Adult Subjects With Late Onset Pompe Disease (LOPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10075702 Pompe's disease late onset LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) SE (Completed) HU (Completed) BE (Completed) SK (Completed) ES (Completed) NL (Completed) BG (Prematurely Ended) SI (Completed) GR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002194-28 Sponsor Protocol Number: NL81713.078.22 Start Date*: 2023-03-20
    Sponsor Name:Erasmus MC
    Full Title: Phase I/II study to determine the safety, immunogenicity and efficacy of Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination (HEB-PEP-Study)
    Medical condition: HBeAg negative chronic HBV
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001468-12 Sponsor Protocol Number: PEN-221-001 Start Date*: 2017-01-16
    Sponsor Name:Tarveda Therapeutics, Inc.
    Full Title: A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with somatostatin receptor 2 expressing ad...
    Medical condition: Somatostatin receptor 2 (SSTR2) expressing advanced cancers, including gastroenteropancreatic (GEP) cancer or lung cancer or thymus cancer or other NETs (Neuroendocrine tumour) or small cell lung c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-009366-13 Sponsor Protocol Number: TDE-PH-308 Start Date*: 2009-09-02
    Sponsor Name:United Therapeutics Corporation
    Full Title: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hyp...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) AT (Completed) DE (Completed) ES (Completed) SE (Completed) PT (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006068-32 Sponsor Protocol Number: CDX110-04 Start Date*: 2012-07-04
    Sponsor Name:Celldex Therapeutics, Inc
    Full Title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma ...
    Medical condition: Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Completed) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001626-26 Sponsor Protocol Number: OMT28-C0201 Start Date*: 2019-01-23
    Sponsor Name:OMEICOS Therapeutics GmbH
    Full Title: A Placebo-controlled, double-blind, Randomized, dose finding phase II study on OMT-28 in MaIntenance of Sinus rhythm after Electrical cardioversion in patients with persistent Atrial Fibrillation (...
    Medical condition: Persistent atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-002117-19 Sponsor Protocol Number: ITCA650-CLP-105 Start Date*: 2013-02-27
    Sponsor Name:Intarcia Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients wit...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    16.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2023-001028-40 Sponsor Protocol Number: RIV-PN-201 Start Date*: 2024-01-15
    Sponsor Name:United Therapeutics Corp
    Full Title: Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study
    Medical condition: Persistant Pulmonary Hypertension of the Newborn (PPHN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-006637-19 Sponsor Protocol Number: CARDIOL100-002 Start Date*: 2022-12-01
    Sponsor Name:Cardiol Therapeutics Inc.
    Full Title: Impact of CardiolRxTM on Myocardial Recovery in Patients with Acute Myocarditis A double-blind, placebo-controlled trial (ARCHER)
    Medical condition: Acute Myocarditis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000932 Acute myocarditis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002728-13 Sponsor Protocol Number: D/P3/07/4 Start Date*: 2008-03-17
    Sponsor Name:Diamyd Therapeutics AB
    Full Title: A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of Diamyd® on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabe...
    Medical condition: Patients for the proposed trial are those with recent onset type 1 diabetes (diagnosed within 3 months at screening).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NL (Ongoing) FI (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) SI (Prematurely Ended) GB (Prematurely Ended) FR (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004664-18 Sponsor Protocol Number: NEOD001-OLE251 Start Date*: 2017-08-08
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO)
    Medical condition: The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who completed Study NEOD001 201
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001187-33 Sponsor Protocol Number: APD811-301 Start Date*: 2019-02-12
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
    Medical condition: pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000601-77 Sponsor Protocol Number: 5051-201 Start Date*: 2019-12-11
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, then Dose Expansion, in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IE (Prematurely Ended) ES (Temporarily Halted) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Restarted) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 01:51:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA